Document:

Amendment No. 9 dated as of April 15, 2004

 Exhibit 10.2 
  
 AMENDMENT NO. 9 
  
 This Amendment No. 9 dated as of April 15, 2004 (“Agreement”) is among Team, Inc., a Texas corporation (“Borrower”), the
financial institutions party to the Credit Agreement described below (“Banks”), and Bank of America, N.A., successor by merger to NationsBank, N.A., as agent for the Banks (“Agent”). 
  
 INTRODUCTION 
  
 A. The Borrower, the Agent, and the Banks are parties to the Credit Agreement
dated as of August 28, 1998, as amended by Amendment No. 1 and Consent dated as of April 9, 1999, Amendment No. 2 and Consent dated as of May 1, 2000, the Third Amendment dated as of July 10, 2000, Amendment No. 4 dated as of November 30, 2000,
Amendment No. 5 dated as of April 25, 2001, Amendment No. 6 dated as of October 31, 2001, Amendment No. 7 dated as of March 13, 2002, and Amendment No. 8 dated as of December 18, 2002 (as so amended, the “Credit Agreement”).

  
 B. The Borrower has requested that the Banks, and the Banks
have agreed to, increase the amount of the Loan A Commitment under the Credit Agreement to $22,500,000.00 in connection with the proposed acquisition (the “Acquisition”) of all of the outstanding capital stock of Thermal Solutions,
Inc., a Colorado corporation (“Thermal”), pursuant to the Stock Purchase Agreement dated as of April 1, 2004 (“Purchase Agreement”) among (1) the Borrower, (2) Team Industrial Services, Inc. a Texas corporation and
an indirect wholly-owned subsidiary of Borrower (“Buyer”), (3) Michael J. Urban, Emmett J. Lescroart, Frank Kargol, Tom Twedt, Kurt Hand, James A. Fawcett, Christine Mitcheltree, Christopher Bicket, Michael Pajdzik, and Kieth
Hildebrandt who, together with the preceding individuals, constitute all of the shareholders of Thermal, and (4) Michael J. Urban, in his capacity as the shareholder representative. 
  
 THEREFORE, the Borrower, the Agent, and the Banks hereby agree as follows: 
  
 Section 1. Definitions. Unless otherwise defined in this Agreement,
terms used in this Agreement which are defined in the Credit Agreement shall have the meanings assigned to such terms in the Credit Agreement. 
  
 Section 2. Amendment to the Credit Agreement. 
  
 (a) The amount of $12,500,000 set forth under the Bank’s name on the signature pages of the Credit Agreement as its Loan A Commitment is hereby
deleted and replaced with “$22,500,000”. 
  
 (b) The
definition of “Loan A Commitment Termination Date” in Section 1.1 of the Credit Agreement is amended and replaced in its entirety by the following: 
  
 “Loan A Commitment Termination Date” means April 15, 2006. 

 (c) The definition of “Loan A Maturity Date” in Section 1.1 of the Credit Agreement is
amended and replaced in its entirety by the following: 
  
 “Loan A Maturity Date” means April 15, 2006. 
  
 (d) Section 2.6 Fees. Section 2.6(a) of the Credit Agreement is amended and replaced in its entirety by the following: 
  
 Section 3. Consent, Waiver, and Notification. 
  
 (a) Upon the satisfaction of the conditions to the effectiveness of this Agreement, the Banks hereby consent to the acquisition under the Purchase
Agreement. 
  
 (b) The Agent hereby waives, for purposes of this
Acquisition only, the reporting requirement of Borrower set forth in Section 5.2(d) of the Credit Agreement whereby Borrower is required to furnish to Agent an Acquisition Certificate duly certified by a Responsible Officer of Borrower in connection
with this Acquisition. 
  
 (c) Pursuant to Section 4.10 of the
Credit Agreement, the Borrower hereby notifies the Banks and the Agent that Thermal will become a Subsidiary of the Borrower upon consummation of the Purchase Agreement. 
  
 Section 4. Representations and Warranties. The Borrower represents and warrants to the Agent and the Banks that:

  
 (a) the representations and warranties set forth in the
Credit Agreement and in the other Credit Documents are true and correct in all material respects as of the date of this Agreement; 
  
 (b) (i) the execution, delivery and performance of this Agreement are within the corporate power and authority of the Borrower and have been duly
authorized by appropriate proceedings and (ii) this Agreement constitutes a legal, valid, and binding obligation of the Borrower, enforceable in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, or similar laws affecting the rights of creditors generally and general principles of equity; and 
  
 (c) as of the effectiveness of this Agreement, no Default or Event of Default has occurred and is continuing. 
  
 Section 5. Facility Fee. The Borrower shall pay to Agent a facility
fee in the amount of $45,000 in connection with this Agreement and the increase of the Loan A Commitment. 
  

 -2- 

 Section 6. Effectiveness. This Agreement shall become effective as of the date of this Agreement,
and the Credit Agreement shall be amended as provided in this Agreement, upon the occurrence of the following conditions precedent: 
  
 (a) the Borrower shall have duly and validly executed and delivered originals of this Agreement and the Banks and Agent shall have executed and delivered
this Agreement; 
  
 (b) the Borrower shall have paid the facility
fee referred to above in Section 5 and delivered or shall have caused to be delivered to the Agent the documents and items listed on Exhibit A attached hereto, together with any other documents reasonably requested by the Agent to document
the agreements and intent of the Credit Documents, each in form and substance satisfactory to the Agent. 
  
 (c) the representations and warranties in this Agreement shall be true and correct in all material respects; and 
  
 (d) the Acquisition shall have been consummated pursuant to the terms of the
Purchase Agreement without any amendments thereto. 
  
 Section 7.
Effect on Credit Documents. 
  
 (a) Except as amended
herein, the Credit Agreement and the Credit Documents remain in full force and effect as originally executed. Nothing herein shall act as a waiver of any of the Agent’s or Banks’ rights under the Credit Documents, as amended, including the
waiver of any Default or Event of Default, however denominated. 
  
 (b) This Agreement is a Credit Document for the purposes of the provisions of the other Credit Documents. Without limiting the foregoing, any breach of representations, warranties, and covenants under this Agreement may be a Default or
Event of Default under other Credit Documents. 
  
 Section 8.
Post Closing Requirements. The Borrower shall deliver to Agent, no later than 5:00 p.m. Houston, Texas time on May 28, 2004, certificates of good standing for Thermal from California, Arizona, Indiana, Tennessee, Pennsylvania, and the U.S.
Virgin Islands and any other items listed as Post Closing Requirements on the attached Exhibit A hereto. The failure of Borrower to deliver to Agent, on or prior to the required date set for above, any of the required documents under this
Section 8 shall constitute an Event of Default under the Credit Agreement. 
  
 Section 9. Choice of Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Texas. 
  
 Section 10. Counterparts. This Agreement may be signed in any number of counterparts, each of which shall be an
original. 
  
 Section 11. Arbitration. 
  
 (a) Any controversy or claim between or among the parties hereto, including
those arising out of or relating to this Agreement or the Credit Documents, including any claim based on or arising from an alleged tort, shall be determined by binding arbitration in accordance with the Federal Arbitration Act (or if not
applicable, the applicable state law), the rules of practice and procedure for the arbitration of commercial disputes of Judicial Arbitration and Mediation Services, Inc. (“JAMS”), and the “special rules” set forth in paragraph
(b) below. In the event of 
  

 -3- 

 any inconsistency, the special rules shall control. Judgment upon any arbitration award may be entered in any court
having jurisdiction. Any party to this Agreement may bring an action, including a summary or expedited proceeding, to compel arbitration of any controversy or claim to which this Agreement or any of the Credit Documents applies in any court having
jurisdiction over such action. 
  
 (b) The arbitration shall be
conducted in Houston, Texas, and administered by JAMS, who shall appoint an arbitrator; if JAMS is unable or legally precluded from administering the arbitration, then the American Arbitration Association shall serve. All arbitration hearings shall
be commenced within 90 days of the demand for arbitration; further, the arbitrator shall only be permitted to extend the commencement of such hearing for up to an additional 60 days and only after showing cause. The payment of costs and fees
associated with the arbitration shall be allocated between the parties by the arbitrator. 
  
 (c) Nothing in this Agreement shall be deemed to (i) limit the applicability of any otherwise applicable statutes of limitation or repose and any waivers contained in this Agreement or the Credit Documents; or (ii) be
a waiver by the Agent or any Lender of the protection afforded to it by 12 U.S.C. Sec. 91 or any substantially equivalent state law; or (iii) limit the right of the Agent or any Lender hereto (A) to exercise self help remedies such as setoff, or (B)
to take action to enforce rights under any security or support for the Indebtedness, including foreclosing on collateral and making claims under guaranties, to the extent permitted under the Credit Documents, or (C) to obtain from a court
provisional or ancillary remedies such as injunctive relief, writ of possession, or the appointment of a receiver. The Agent and any Lender may, to the extent permitted under the Credit Documents, exercise such self help rights, enforce rights
related to security or support, or obtain such provisional or ancillary remedies before, during, or after the pendency of any arbitration proceeding brought pursuant to this Agreement. Neither this exercise of self help remedies nor the institution
or maintenance of an action for foreclosure or provisional or ancillary remedies shall constitute a waiver of the right of any party, including the claimant in any such action, to arbitrate the merits of the controversy or claim occasioning resort
to such remedies. 
  
 PURSUANT TO SECTION 26.02 OF THE TEXAS
BUSINESS AND COMMERCE CODE, A LOAN AGREEMENT IN WHICH THE AMOUNT INVOLVED IN THE LOAN AGREEMENT EXCEEDS $50,000 IN VALUE IS NOT ENFORCEABLE UNLESS THE LOAN AGREEMENT IS IN WRITING AND SIGNED BY THE PARTY TO BE BOUND OR THAT PARTY’S AUTHORIZED
REPRESENTATIVE. THE RIGHTS AND OBLIGATIONS OF THE PARTIES TO AN AGREEMENT SUBJECT TO THE PRECEDING PARAGRAPH SHALL BE DETERMINED SOLELY FROM THE WRITTEN LOAN AGREEMENT, AND ANY PRIOR ORAL AGREEMENTS BETWEEN THE PARTIES ARE SUPERSEDED BY AND MERGED
INTO THE LOAN AGREEMENT. THIS WRITTEN AGREEMENT AND THE CREDIT DOCUMENTS, AS DEFINED IN THE CREDIT AGREEMENT, REPRESENT THE FINAL AGREEMENT AMONG THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL
AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS AMONG THE PARTIES. 
  

 -4- 

 EXECUTED to be effective as of the date first above written. 
  

			
	 TEAM, INC.

		
	 By:
	 	 /s/ Ted W. Owen

	 	 	 Ted W. Owen

	 	 	 Vice President and CFO

	
	BANK OF AMERICA, N.A., successor by merger to NationsBank, N.A., as Agent and Bank
		
	 By:
	 	 /s/ Gary L. Mingle

	 	 	 Gary L. Mingle

	 	 	 Senior Vice President

 Exhibit A 
 Closing IndexVoting Agreement

 Exhibit 10.1 
  
 VOTING AGREEMENT 
  
 This Voting Agreement (this “Agreement”) is made and entered into as of April 16, 2004, by and between the stockholders set forth
on the signature pages hereto (each a “Stockholder” and collectively, the “Stockholders”) and SeraCare Life Sciences, Inc., a California corporation (“Buyer”). 
  
 RECITALS 
  
 WHEREAS, Buyer and Boston Biomedica, Inc., a Massachusetts corporation (“Parent”) are parties to
that certain Asset Purchase Agreement dated as of April 16, 2004 (the “Purchase Agreement”) by and among Buyer, Parent and BBI Biotech Research Laboratories, Inc., a Massachusetts corporation. In order to induce Buyer to
enter into the Purchase Agreement, the Stockholders have entered into this Agreement with Buyer. Each Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”)) of such number of shares of the outstanding Common Stock, $0.01 par value per share, of Parent as is indicated on the final page of this Agreement (the “Shares”). 
  
 AGREEMENT 
  
 NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties agree as follows: 
  
 1. Agreement to Retain
Shares. 
  
 (a) Transfer and Encumbrance.
Each Stockholder agrees not to (i) transfer (which term shall include, without limitation, any sale, exchange, assignment, gift, pledge, hypothecation or other disposition), or consent to any transfer of, any or all of the Shares or any New Shares
(as such term is defined in Section 1(b)) or any interest therein, or otherwise dispose of or create or permit to exist any lien on such shares; (ii) enter into any contract, option or other agreement or understanding with respect to any transfer of
any or all of such shares or any interest therein; (iii) grant any proxy, power-of-attorney or other authorization in or with respect to such shares; (iv) deposit such shares into a voting trust or enter into a voting agreement or arrangement with
respect to such shares; or (v) take any other action that would in any way restrict, limit or interfere with the performance of such Stockholder’s obligations hereunder or the transactions contemplated hereby or by the Purchase Agreement, at
any time prior to the Expiration Date. As used herein, the term “Expiration Date” shall mean the earlier to occur of (i) the Closing (as such term is defined in the Purchase Agreement), or (ii) the date of termination of the
Purchase Agreement. 
  
 (b) New Shares. Each
Stockholder agrees that any shares of capital stock of Parent that such Stockholder purchases or with respect to which such Stockholder otherwise acquires beneficial ownership after the date of this Agreement and prior to the Expiration Date
(“New Shares”) shall be subject to the terms and conditions of this Agreement to the same extent as if they constituted Shares. 

 2. Agreement to Vote Shares. Prior to the Expiration Date, at every meeting of the
stockholders of Parent called with respect to any of the following, and at every adjournment thereof, and on every action or approval by written consent of the stockholders of Parent with respect to any of the following, each Stockholder shall vote
the Shares and any New Shares (to the extent such New Shares have voting rights) (i) in favor of approval of the Purchase Agreement and any matter necessary to facilitate the consummation of the Purchase Agreement and all transactions contemplated
thereby, and (ii) against any Acquisition Proposal (as such term is defined in the Purchase Agreement), or any other action or agreement that would result in a breach of any covenant, representation or warranty or any other obligation or agreement
of Parent under the Purchase Agreement or which could reasonably be expected to result in any of the conditions to Parent’s obligations under the Purchase Agreement not being fulfilled; provided, however, that such Stockholder shall not be
required to vote the Shares and any New Shares in favor of approval of the matters identified in clause (i) or against the matters identified in clause (ii) of this Section 2 if (A) a Superior Offer (as such term is defined in the Purchase
Agreement) is made after the date of this Agreement, and (B) in response to such Superior Offer the Board of Directors of Parent withholds, withdraws, amends or modifies its recommendation in favor of the Stockholder Approval Matters (as such term
is defined in the Purchase Agreement) in a manner materially adverse to Buyer because the Board of Directors of Parent has reasonably concluded in good faith, after consultation with its outside counsel, that the failure to withhold, withdraw, amend
or modify such recommendation would violate its fiduciary obligations under applicable law. 
  
 3. Irrevocable Proxy; Power of Attorney. Without limiting the generality of the foregoing, each Stockholder hereby irrevocably constitutes and appoints Buyer or its designee as its attorney and proxy,
with full power of substitution and re-substitution to vote such Stockholder’s Shares and any New Shares (to the extent such New Shares have voting rights) for and in the name, place and stead of such Stockholder at any meeting and at any
adjournment thereof, or pursuant to any written consent of stockholders of Parent, in accordance with the agreements set forth in Section 2 hereof. Subject to the provisions of Section 8 below, this proxy and power of attorney is irrevocable (at all
times prior to the Expiration Date) and coupled with an interest. Each Stockholder hereby revokes all other proxies and power of attorney with respect to the Shares and/or any New Shares that it may have heretofore appointed or granted, and no
subsequent proxy or power of attorney shall be granted (and if granted, shall not be effective) by such Stockholder with respect thereto. Concurrently with the execution of this Agreement, each Stockholder agrees to deliver to Buyer a proxy (the
form of which is attached hereto as Schedule 1, the “Proxy”), covering the total number of Shares and New Shares beneficially owned or as to which beneficial ownership is acquired (as such term is defined in Rule 13d-3 under
the Exchange Act) by such Stockholder. 
  
 4. No
Solicitation. 
  
 (a) No Solicitation or
Negotiation. Except as set forth in this Section 4, prior to the Expiration Date, none of the Stockholders shall, directly or indirectly: 
  
 (i) solicit, initiate, encourage or induce the making, submission or announcement of any Acquisition Proposal; 
  

 2 

 (ii) participate in any discussions or negotiations regarding, or furnish to any person any non-public
information with respect to, or take any other action to facilitate any inquiries or the making of any proposal that constitutes or may reasonably be expected to lead to, any Acquisition Proposal; 
  
 (iii) engage in discussions with any person with respect to any Acquisition
Proposal; 
  
 (iv) approve, endorse or recommend any Acquisition
Proposal; or 
  
 (v) enter into any letter of intent or similar
document or any contract, agreement or commitment contemplating or otherwise relating to any Acquisition Transaction (as defined in the Purchase Agreement); provided, however, that a Stockholder may, solely in the Stockholder’s capacity as a
Representative (as such term is defined in the Purchase Agreement) of Parent, take such actions as may be permitted under Section 6.2(a) of the Purchase Agreement, but only if the conditions set forth in Section 6.2(a) for such actions have been
satisfied. 
  
 (b) Notices; Additional Negotiations. In
addition to the obligations of the Stockholders set forth in paragraph (a) of this Section 4, prior to the Expiration Date, each Stockholder shall advise Buyer orally and in writing within 24 hours of the receipt thereof, of any request received by
such Stockholder for nonpublic information which such Stockholder reasonably believes would lead to an Acquisition Proposal or of any Acquisition Proposal, or any inquiry received by such Stockholder with respect to, or which such Stockholder
reasonably believes would lead to any Acquisition Proposal, the material terms and conditions of such request, Acquisition Proposal or inquiry, and the identity of the person or group making any such request, Acquisition Proposal or inquiry. Each
Stockholder will keep Buyer informed (orally and in writing) on a current basis and in all material respects of the status and details (including material amendments or proposed amendments) of any such request, Acquisition Proposal or inquiry.

  
 (c) Cessation of Ongoing Discussions. Each Stockholder
shall cease immediately any and all existing activities, discussions or negotiations with any parties conducted heretofore with respect to any Acquisition Proposal. 
  
 (d) Notwithstanding anything to the contrary stated herein, this Section 4 shall not apply to any of the Stockholders in
their respective capacity as either an officer or director of Parent and any actions undertaken or omissions by a Stockholder in any such capacity shall be governed exclusively by the Purchase Agreement. 
  
 5. Representations, Warranties and Covenants of the
Stockholder. Each Stockholder hereby represents, warrants and covenants to Buyer that (i) such Stockholder is the beneficial owner of the Shares, which at the date of this Agreement and at all times up until the Expiration Date will be free
and clear of any liens, claims, options, charges or other encumbrances (except pursuant to marital property laws) that would interfere with the voting of the Shares in accordance with this Agreement or the granting of any proxy with respect thereto;
(ii) such Stockholder does not beneficially own any shares of capital stock of Parent other than 
  

 3 

 the Shares; (iii) such Stockholder has full power and authority to make, enter into and carry out the terms of this
Agreement and the Proxy; and (iv) the execution and delivery of this Agreement by such Stockholder and the consummation by such Stockholder of the transactions contemplated hereby have been duly authorized by all necessary action, if any, on the
part of such Stockholder. 
  
 6. Additional
Documents. Each Stockholder hereby covenants and agrees to execute and deliver any additional documents necessary or desirable to carry out the purpose and intent of this Agreement. 
  
 7. Consent and Waiver. Each Stockholder hereby gives any
consents or waivers that are reasonably required for the consummation of the Purchase Agreement under the terms of any agreement to which such Stockholder is a party or pursuant to any rights such Stockholder may have. 
  
 8. Termination. This Agreement and each of the Proxies
delivered in connection herewith shall terminate and shall have no further force or effect as of the Expiration Date; provided, however, that no such termination of this Agreement or the Proxies shall relieve the Stockholders from any liability for
any breach of this Agreement or the Proxies prior to their respective termination. Notwithstanding any other provision of this Agreement, the Stockholders, acting unanimously, may terminate this Agreement and any Proxy and be released from all
obligations to vote their respective Shares, in accordance with the provisions of this Agreement or to have their respective Shares voted in accordance with any Proxy in the event the Purchase Agreement is materially amended or modified. For
purposes of this Section 8, an extension of the terminate date set forth in Section 11.1(b) of the Purchase Agreement shall not be deemed to be a material amendment or modification of the Purchase Agreement. 
  
 9. Miscellaneous. 
  
 (a) Amendments and Waivers. Any term of this Agreement may be
amended or waived with the written consent of the parties or their respective successors and assigns. Any amendment or waiver effected in accordance with this Section 9(a) shall be binding upon the parties and their respective successors and
assigns. 
  
 (b) Governing Law. This Agreement and
all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the Commonwealth of Massachusetts, without giving effect to principles of
conflicts of law. Each of the parties to this Agreement consents to the exclusive jurisdiction and venue of the state and federal courts located in or for the State of Delaware in connection with any matter based upon or arising out of this
Agreement or the matters contemplated herein, agrees that process may be served upon it in any manner authorized by the laws of the State of Delaware for such persons and waives and covenants not to assert or plead any objection which it might
otherwise have to such jurisdiction and such process. 
  
 (c)
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. 
  

 4 

 (d) Titles and Subtitles. The headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 
  
 (e) Notices. All notices, requests, demands and other communications which are required or may be given under this Agreement shall be in writing and shall be deemed to have been duly given when received
if personally delivered; when transmitted if transmitted by telecopy, electronic or digital transmission method; the day after it is sent, if sent for next day delivery to a domestic address by recognized overnight delivery service
(e.g., Federal Express); and upon receipt, if sent by certified or registered mail, return receipt requested. In each case notice shall be sent to: 
  
 If to Buyer, addressed to: 
  
 SeraCare Life Science, Inc. 
 1935 Avenida del Oro, Suite F 
 Oceanside, CA 92056 
 Attention: President 
 Facsimile:  (760) 806-8933 
  
 With a copy to:

  
 O’Melveny & Myers LLP 
 114 Pacific, Suite 100 
 Irvine, CA 92618-3318 
 Attention: Andor D. Terner, Esq. 
 Facsimile:  (949) 737-2300 
  
 If to a Stockholder, to the address for such Stockholder set forth on the signature page hereto. 
  
 or to such other place and with such other copies as any party may designate as to itself by
written notice to the others. 
  
 (f) Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith, in order to maintain the position enjoyed by each party as close as possible to that under
the provision rendered unenforceable. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement
shall be interpreted as if such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms. 
  
 (g) Assignment. This Agreement and all of the terms and provisions hereof shall be binding upon, and inure to the benefit of, the parties
hereto and their respective successors and permitted assigns, but, except as otherwise specifically provided herein, neither this Agreement nor any of the rights, interests or obligations of either party may be assigned without the prior written
consent of the other party (any such attempted assignment shall be void). 
  

 5 

 (h) Remedies. Each Stockholder acknowledges that if such Stockholder fails to perform any
of its covenants, agreements or obligations under this Agreement immediate and irreparable harm or injury would be caused to Buyer for which money damages would not be an adequate remedy. In such event, each Stockholder agrees that Buyer shall have
the right, in addition to any other rights it may have, to specific performance of this Agreement. Accordingly, if Buyer should institute an action or proceeding seeking specific enforcement of the provisions hereof, each Stockholder hereby waives
the claim or defense that Buyer has an adequate remedy at law and hereby agrees not to assert in any such action or proceeding the claim or defense that such a remedy at law exists. Each Stockholder further agrees to waive any requirements for the
securing or posting of any bond in connection with obtaining any such equitable relief. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other
remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. 
  

[SIGNATURE PAGE TO FOLLOW] 
  

 6 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed as of the date first above
written. 
  

			
	SERACARE LIFE SCIENCES, INC.,
	 a California corporation

		
	 By:
	 	 /s/ Michael F. Crowley II

	 Name:
	 	MICHAEL F. CROWLEY II
	 Title:
	 	Chief Executive Officer
		
	 Address:
	 	 1935 Avenida del Oro, Suite F

	 	 	 Oceanside, CA 92056

	 	 	 Attention: President

	 	 	 Facsimile No.: (760) 806-8933

	
	STOCKHOLDER
		
	 By:
	 	 /s/ Richard P. Kiphart

	 Name:
	 	RICHARD P. KIPHART
	 Title:
	 	—
		
	 Address:
	 	608 Elm Street
	 	 	 Winnetka, IL 60093

  
  

			
	 Shares beneficially owned:

		
	 Class of Shares

	 	Number

	 Common Stock
	 	1,542,985

  

			
	STOCKHOLDER
	
	SHORELINE MICRO-CAP FUND I LP
		
	 By:
	 	 /s/ Richard P. Kiphart

	 Name:
	 	RICHARD P. KIPHART
	 Title:
	 	Partner
		
	 Address:
	 	 c/o William Blair & Co. (Richard Kiphart)

	 	 	 222 W. Adams Street

	 	 	 Chicago, IL 60606

  

			
	 Shares beneficially owned:

		
	 Class of Shares

	 	Number

	 Common Stock
	 	365,613

  

 S-1 

			
	STOCKHOLDER
		
	 By:
	 	 /s/ Rebecca S. Kiphart

	 Name:
	 	REBECCA S. KIPHART
	 Title:
	 	—
		
	 Address:
	 	 608 Elm Street

	 	 	 Winnetka, IL 60093

  

			
	 Shares beneficially owned:

		
	 Class of Shares

	 	Number

	 Common Stock
	 	90,000

  

 S-2 

 SCHEDULE 1 
  
 IRREVOCABLE PROXY TO VOTE STOCK OF PARENT 
  
 The undersigned stockholder of Boston Biomedica, Inc., a Massachusetts corporation (“Parent”), hereby
irrevocably appoints the Chief Executive Officer and Chief Financial Officer from time to time (currently Michael Crowley, Jr. and Tim Hart, respectively) of SeraCare Life Sciences, Inc., a California corporation (“Buyer”), and each
of them, as the sole and exclusive attorneys and proxies of the undersigned, with full power of substitution and resubstitution, to vote and exercise all voting and related rights (to the full extent that the undersigned is entitled to do so) with
respect to all of the shares of capital stock of Parent that now are or hereafter may be beneficially owned by the undersigned, and any and all other shares or securities of Parent issued or issuable in respect thereof on or after the date hereof
(collectively, the “Shares”) in accordance with the terms of this Proxy. The Shares beneficially owned by the undersigned stockholder of Parent as of the date of this Proxy are listed on the final page of this Proxy. Upon the
undersigned’s execution of this Proxy, any and all prior proxies given by the undersigned with respect to any Shares are hereby revoked and the undersigned agrees not to grant any subsequent proxies with respect to the Shares and this subject
matter until after the Expiration Date (as defined below). 
  
 This Proxy is irrevocable, is granted pursuant to that certain Voting Agreement of even date herewith, by and between Buyer and the undersigned stockholder, among others (the “Voting Agreement”), and is granted in
consideration of Buyer entering into that certain Asset Purchase Agreement, of even date herewith, by and among Parent, Buyer and BBI Biotech Research Laboratories, Inc., a Massachusetts corporation (the “Purchase Agreement”). This
Proxy shall terminate on the Expiration Date (as such term is defined in the Voting Agreement). Notwithstanding any other provision of this Proxy, the undersigned stockholder may terminate this Proxy and be released from all obligations to vote his
Shares in accordance with the provisions of this Proxy in the event the Voting Agreement is terminated pursuant to Section 8 of the Voting Agreement. 
  
 The attorneys and proxies named above, and each of them, are hereby authorized and empowered by the undersigned, at any time prior to the Expiration Date,
to act as the undersigned’s attorney and proxy to vote the Shares, and to exercise all voting and other rights of the undersigned with respect to the Shares (including, without limitation, the power to execute and deliver written consents
pursuant to Section 43 of Chapter 156B of the Annotated Laws of Massachusetts, or such successor provision of the law contained in Chapter 156D of the Massachusetts Business Corporation Act, which becomes effective on July 1, 2004), at every annual,
special or adjourned meeting of the stockholders of Parent and in every written consent in lieu of such meeting (i) in favor of approval of the Purchase Agreement and in favor of any matter necessary to facilitate the Purchase Agreement, and (ii)
against any Acquisition Proposal (as such term is defined in the Purchase Agreement), or any other action or agreement that would result in a breach of any covenant, representation or warranty or any other obligation or agreement of Parent under the
Purchase Agreement or which could reasonably be expected to result in any of the conditions to Parent’s obligations under the Purchase Agreement not being 
  

 Schedule 1-1 

 fulfilled; provided, however, that the undersigned shall not be required to vote the Shares and any New Shares in favor
of approval of the matters identified in clause (i) or against the matters identified in clause (ii) of this paragraph if (A) a Superior Offer (as such term is defined in the Purchase Agreement) is made after the date of this Agreement, and (B) in
response to such Superior Offer the Board of Directors of Parent withholds, withdraws, amends or modifies its recommendation in favor of the Stockholder Approval Matters (as such term is defined in the Purchase Agreement) in a manner materially
adverse to Buyer because the Board of Directors of Parent has reasonably concluded in good faith, after consultation with its outside counsel, that the failure to withhold, withdraw, amend or modify such recommendation would violate its fiduciary
obligations under applicable law. The attorneys and proxies named above may not exercise this Proxy on any other matter except as provided above. The undersigned stockholder may vote the Shares on all other matters. 
  
 Any obligation of the undersigned hereunder shall be binding upon the
successors and assigns of the undersigned. 
  
 [SIGNATURE PAGE TO
FOLLOW] 
  

 Schedule 1-2 

 IN WITNESS WHEREOF, the undersigned has caused this Proxy to be executed as of the date set forth below.

  
 Dated: April 16, 2004 
  

	
	 /s/ Richard Kiphart

	RICHARD KIPHART

  

			
	 Shares beneficially owned:

		
	 Class of Shares

	 	Number

	 Common Stock
	 	1,542,985*

	*	Includes (i) 90,000 shares of Common Stock held of record by Rebecca Kiphart, (ii) 357,791 shares of Common Stock held of record by Shoreline Micro-Cap Fund I LP, (iii) warrants to
purchase an aggregate of 7,822 shares of Common Stock held of record by Shoreline Micro-Cap Fund I LP, (iv) warrants to purchase an aggregate of 27,734 shares of Common Stock held of record by Richard Kiphart. 

  

 Schedule 1-3 

 SCHEDULE 1 
  
 IRREVOCABLE PROXY TO VOTE STOCK OF PARENT 
  
 The undersigned stockholder of Boston Biomedica, Inc., a Massachusetts corporation (“Parent”), hereby
irrevocably appoints the Chief Executive Officer and Chief Financial Officer from time to time (currently Michael Crowley, Jr. and Tim Hart, respectively) of SeraCare Life Sciences, Inc., a California corporation (“Buyer”), and each
of them, as the sole and exclusive attorneys and proxies of the undersigned, with full power of substitution and resubstitution, to vote and exercise all voting and related rights (to the full extent that the undersigned is entitled to do so) with
respect to all of the shares of capital stock of Parent that now are or hereafter may be beneficially owned by the undersigned, and any and all other shares or securities of Parent issued or issuable in respect thereof on or after the date hereof
(collectively, the “Shares”) in accordance with the terms of this Proxy. The Shares beneficially owned by the undersigned stockholder of Parent as of the date of this Proxy are listed on the final page of this Proxy. Upon the
undersigned’s execution of this Proxy, any and all prior proxies given by the undersigned with respect to any Shares are hereby revoked and the undersigned agrees not to grant any subsequent proxies with respect to the Shares and this subject
matter until after the Expiration Date (as defined below). 
  
 This Proxy is irrevocable, is granted pursuant to that certain Voting Agreement of even date herewith, by and between Buyer and the undersigned stockholder, among others (the “Voting Agreement”), and is granted in
consideration of Buyer entering into that certain Asset Purchase Agreement, of even date herewith, by and among Parent, Buyer and BBI Biotech Research Laboratories, Inc., a Massachusetts corporation (the “Purchase Agreement”). This
Proxy shall terminate on the Expiration Date (as such term is defined in the Voting Agreement). Notwithstanding any other provision of this Proxy, the undersigned stockholder may terminate this Proxy and be released from all obligations to vote its
Shares in accordance with the provisions of this Proxy in the event the Voting Agreement is terminated pursuant to Section 8 of the Voting Agreement. 
  
 The attorneys and proxies named above, and each of them, are hereby authorized and empowered by the undersigned, at any time prior to the Expiration Date,
to act as the undersigned’s attorney and proxy to vote the Shares, and to exercise all voting and other rights of the undersigned with respect to the Shares (including, without limitation, the power to execute and deliver written consents
pursuant to Section 43 of Chapter 156B of the Annotated Laws of Massachusetts, or such successor provision of the law contained in Chapter 156D of the Massachusetts Business Corporation Act, which becomes effective on July 1, 2004), at every annual,
special or adjourned meeting of the stockholders of Parent and in every written consent in lieu of such meeting (i) in favor of approval of the Purchase Agreement and in favor of any matter necessary to facilitate the Purchase Agreement, and (ii)
against any Acquisition Proposal (as such term is defined in the Purchase Agreement), or any other action or agreement that would result in a breach of any covenant, representation or warranty or any other obligation or agreement of Parent under the
Purchase Agreement or which could reasonably be expected to result in any of the conditions to Parent’s obligations under the Purchase Agreement not being 
  

 Schedule 1-1 

 fulfilled; provided, however, that the undersigned shall not be required to vote the Shares and any New Shares in favor
of approval of the matters identified in clause (i) or against the matters identified in clause (ii) of this paragraph if (A) a Superior Offer (as such term is defined in the Purchase Agreement) is made after the date of this Agreement, and (B) in
response to such Superior Offer the Board of Directors of Parent withholds, withdraws, amends or modifies its recommendation in favor of the Stockholder Approval Matters (as such term is defined in the Purchase Agreement) in a manner materially
adverse to Buyer because the Board of Directors of Parent has reasonably concluded in good faith, after consultation with its outside counsel, that the failure to withhold, withdraw, amend or modify such recommendation would violate its fiduciary
obligations under applicable law. The attorneys and proxies named above may not exercise this Proxy on any other matter except as provided above. The undersigned stockholder may vote the Shares on all other matters. 
  
 Any obligation of the undersigned hereunder shall be binding upon the
successors and assigns of the undersigned. 
  
 [SIGNATURE PAGE TO
FOLLOW] 
  

 Schedule 1-2 

 IN WITNESS WHEREOF, the undersigned has caused this Proxy to be executed as of the date set forth below.

  
 Dated: April 16, 2004 
  

			
	 SHORELINE MICRO-CAP FUND I LP

		
	 By:
	 	 /s/ Richard P. Kiphart

	 Name:
	 	RICHARD P. KIPHART
	 Title:
	 	Partner

  
  

				
	 Shares beneficially owned:
	  

		
	 Class of Shares

	 	Number

	 
	 Common Stock
	 	365,613	*

	*	Includes warrants to purchase an aggregate of 7,822 shares of Common Stock. 

  

 Schedule 1-3 

 SCHEDULE 1 
  
 IRREVOCABLE PROXY TO VOTE STOCK OF PARENT 
  
 The undersigned stockholder of Boston Biomedica, Inc., a Massachusetts corporation (“Parent”), hereby
irrevocably appoints the Chief Executive Officer and Chief Financial Officer from time to time (currently Michael Crowley, Jr. and Tim Hart, respectively) of SeraCare Life Sciences, Inc., a California corporation (“Buyer”), and each
of them, as the sole and exclusive attorneys and proxies of the undersigned, with full power of substitution and resubstitution, to vote and exercise all voting and related rights (to the full extent that the undersigned is entitled to do so) with
respect to all of the shares of capital stock of Parent that now are or hereafter may be beneficially owned by the undersigned, and any and all other shares or securities of Parent issued or issuable in respect thereof on or after the date hereof
(collectively, the “Shares”) in accordance with the terms of this Proxy. The Shares beneficially owned by the undersigned stockholder of Parent as of the date of this Proxy are listed on the final page of this Proxy. Upon the
undersigned’s execution of this Proxy, any and all prior proxies given by the undersigned with respect to any Shares are hereby revoked and the undersigned agrees not to grant any subsequent proxies with respect to the Shares and this subject
matter until after the Expiration Date (as defined below). 
  
 This Proxy is irrevocable, is granted pursuant to that certain Voting Agreement of even date herewith, by and between Buyer and the undersigned stockholder, among others (the “Voting Agreement”), and is granted in
consideration of Buyer entering into that certain Asset Purchase Agreement, of even date herewith, by and among Parent, Buyer and BBI Biotech Research Laboratories, Inc., a Massachusetts corporation (the “Purchase Agreement”). This
Proxy shall terminate on the Expiration Date (as such term is defined in the Voting Agreement). Notwithstanding any other provision of this Proxy, the undersigned stockholder may terminate this Proxy and be released from all obligations to vote her
Shares in accordance with the provisions of this Proxy in the event the Voting Agreement is terminated pursuant to Section 8 of the Voting Agreement. 
  
 The attorneys and proxies named above, and each of them, are hereby authorized and empowered by the undersigned, at any time prior to the Expiration Date,
to act as the undersigned’s attorney and proxy to vote the Shares, and to exercise all voting and other rights of the undersigned with respect to the Shares (including, without limitation, the power to execute and deliver written consents
pursuant to Section 43 of Chapter 156B of the Annotated Laws of Massachusetts, or such successor provision of the law contained in Chapter 156D of the Massachusetts Business Corporation Act, which becomes effective on July 1, 2004), at every annual,
special or adjourned meeting of the stockholders of Parent and in every written consent in lieu of such meeting (i) in favor of approval of the Purchase Agreement and in favor of any matter necessary to facilitate the Purchase Agreement, and (ii)
against any Acquisition Proposal (as such term is defined in the Purchase Agreement), or any other action or agreement that would result in a breach of any covenant, representation or warranty or any other obligation or agreement of Parent under the
Purchase Agreement or which could reasonably be expected to result in any of the conditions to Parent’s obligations under the Purchase Agreement not being 
  

 Schedule 1-1 

 fulfilled; provided, however, that the undersigned shall not be required to vote the Shares and any New Shares in favor
of approval of the matters identified in clause (i) or against the matters identified in clause (ii) of this paragraph if (A) a Superior Offer (as such term is defined in the Purchase Agreement) is made after the date of this Agreement, and (B) in
response to such Superior Offer the Board of Directors of Parent withholds, withdraws, amends or modifies its recommendation in favor of the Stockholder Approval Matters (as such term is defined in the Purchase Agreement) in a manner materially
adverse to Buyer because the Board of Directors of Parent has reasonably concluded in good faith, after consultation with its outside counsel, that the failure to withhold, withdraw, amend or modify such recommendation would violate its fiduciary
obligations under applicable law. The attorneys and proxies named above may not exercise this Proxy on any other matter except as provided above. The undersigned stockholder may vote the Shares on all other matters. 
  
 Any obligation of the undersigned hereunder shall be binding upon the
successors and assigns of the undersigned. 
  
 [SIGNATURE PAGE TO
FOLLOW] 
  

 Schedule 1-2 

 IN WITNESS WHEREOF, the undersigned has caused this Proxy to be executed as of the date set forth below.

  
 Dated: April 16, 2004 
  

	
	 /s/ Rebecca Kiphart

	REBECCA KIPHART

  

			
	 Shares beneficially owned:

		
	 Class of Shares

	 	Number

	 Common Stock
	 	90,000

  

 Schedule 1-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]